A Phase 4 interventional study of Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 32nd largest by enrollment, is one of 2 that started in 2014, is one of 17 in phase 4, and was the 27th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 60th largest by enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2014, is one of 26 in phase 4, and was the 41st registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
This was a multi-national, long-term safety study. Patients enrolled in study FTY720D2406 who experienced a cardiovascular event within 24-hours of fingolimod treatment initiation which led to overnight monitoring or met serious adverse event criteria, were eligible to participate in this study.
Patients who experienced a qualifying event in study CFTY720D2406 started study CFTY720D2409 approximately 6 months after the occurrence of the CFTY720D2406 qualifying event.
Patients underwent mandatory assessments on a 6-monthly basis including 12-lead ECG, vital signs. Other assessments were performed as per routine practice.
The primary objective of the study was to estimate the long-term cardiovascular risk of fingolimod in patients who experienced a cardiovascular event during treatment initiation.
The study has no stand-alone secondary objective. However data from the CFTY720D2409 and CFTY720D2406 studies will be pooled to supplement CFTY720DD2406 study and support its primary and secondary objectives of evaluating the safety profile of fingolimod.
The pooled data will be appended to this result upon completion of FDA submission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Treatment with any drug unless it is received as part of a Novartis sponsored MS study lasting less than 1 month
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fingolimod 0.5mg/day tablets taken orally.
Drug: Fingolimod
Fingolimod 0.5 mg tablet
Also known as: FTY720
Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event
Participants from study CFTY720D2406 who experienced a qualifying cardiovascular adverse event were transferred to this study. Qualifying cardiovascular events included, but were not limited to, sudden unexplained death, cardiovascular death, myocardial infarction (MI), Q-wave MI, stroke (ischemic or hemorrhagic), unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, complete heart block, ventricular fibrillation, torsade de pointes, hypertensive emergency and any other suspected life threatening cardiovascular condition.
Time frame: Within 6 months of qualifying event up to 64 months
| Milestone | Fingolimod |
|---|---|
| Started | 6 |
| Completed | 4 |
| Not completed | 2 |
| Withdrew: Administrative problems | 1 |
| Withdrew: Withdrawal by subject | 1 |
Participants from study CFTY720D2406 who experienced a qualifying cardiovascular adverse event were transferred to this study. Qualifying cardiovascular events included, but were not limited to, sudden unexplained death, cardiovascular death, myocardial infarction (MI), Q-wave MI, stroke (ischemic or hemorrhagic), unstable angina requiring hospitalization, congestive heart failure requiring hospitalization, complete heart block, ventricular fibrillation, torsade de pointes, hypertensive emergency and any other suspected life threatening cardiovascular condition.
| participants | Fingolimod |
|---|---|
| Participants Who Experienced at Least One Qualifying Cardiovascular Adverse Event | 0 |
Collected over Within 6 months of qualifying event up to approximately 64 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | 0/6 (0%) | 2/6 (33.3%) | 4/6 (66.7%) |
| Event | Fingolimod |
|---|---|
| LYMPHOPENIABlood and lymphatic system disorders | 1/6 |
| BRONCHITIS VIRALInfections and infestations | 1/6 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 1/6 |
| Event | Fingolimod |
|---|---|
| LYMPHOPENIABlood and lymphatic system disorders | 1/6 |
| HYPOTHYROIDISMEndocrine disorders | 1/6 |
| HAEMORRHOIDAL HAEMORRHAGEGastrointestinal disorders | 1/6 |
| PYREXIAGeneral disorders | 1/6 |
| NASOPHARYNGITISInfections and infestations | 1/6 |
| TRICHOMONIASISInfections and infestations | 1/6 |
| VIRAL PHARYNGITISInfections and infestations | 1/6 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 1/6 |
| FOLATE DEFICIENCYMetabolism and nutrition disorders | 1/6 |
| HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders | 1/6 |
| Age, Customized(participants) | Fingolimod |
|---|---|
| Ages 21 - 47 | 6 |
| Sex: Female, Male(Participants) | Fingolimod |
|---|---|
| Female | 5 |
| Male | 1 |
| Race/Ethnicity, Customized(Participants) | Fingolimod |
|---|---|
| Caucasian | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/
Ran from Sep 2014 to primary completion in Jan 2020, 63 months.
Results were first posted in Feb 2021, 1 year after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 63 months is above that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod